EdgeScore

PALI · Nasdaq

PALISADE BIO, INC.: financial statements

Insufficient data · see the checkFigures in USD, fiscal years

Revenue and net income

Revenue 2019: $15.4KNet income 2019: -$8.4M2019Revenue 2020: $13.5KNet income 2020: -$10.3M2020Revenue 2022: $0Net income 2022: -$14.3M2022Revenue 2023: $250KNet income 2023: -$12.3M2023Revenue 2024: $0Net income 2024: -$14.4M2024Revenue 2025: $0Net income 2025: -$16.8M2025
RevenueNet income

Operating and free cash flow

Operating cash flow 2019: -$7.3MFree cash flow 2019: -$7.3M2019Operating cash flow 2020: -$4.8MFree cash flow 2020: -$4.8M2020Operating cash flow 2022: -$13.4MFree cash flow 2022: -$13.4M2022Operating cash flow 2023: -$11.1MFree cash flow 2023: -$11.1M2023Operating cash flow 2024: -$12.2MFree cash flow 2024: -$12.2M2024Operating cash flow 2025: -$10.8MFree cash flow 2025: -$10.8M2025
Operating cash flowFree cash flow

Margins

Operating 2019: -56071.8%Operating 2020: -68764.8%Operating 2023: -5228.0%Net 2019: -54252.6%Net 2020: -76346.2%Net 2023: -4920.0%201920202022202320242025
GrossOperatingNet

Returns

ROE 2022: -114.3%ROE 2023: -108.7%ROE 2024: -192.7%ROE 2025: -13.0%ROIC 2022: -12937.1%ROA 2019: -126.8%ROA 2020: -341.9%ROA 2022: -90.5%ROA 2023: -87.5%ROA 2024: -132.7%ROA 2025: -12.5%201920202022202320242025
ROEROICROA

Income statement

USD201920202022202320242025Last year
Revenue$15.4K$13.5K$0$250K$0$0
Operating income-$8.6M-$9.3M-$15.7M-$13.1M-$14.9M-$18.1M-22%
EBITDA-$8.5M-$9.3M-$15.7M-$13.1M-$14.9M-$18.1M-22%
Interest expense$8.9K$235K$13.0K$15.0K$12.0K$10.0K-17%
Income tax—$1.0K$0$0$0$0
Net income-$8.4M-$10.3M-$14.3M-$12.3M-$14.4M-$16.8M-16%

Cash flow

USD201920202022202320242025Last year
Operating cash flow-$7.3M-$4.8M-$13.4M-$11.1M-$12.2M-$10.8M+11%
Capital expenditure—$6.0K$10.0K$4.0K$0—
Free cash flow-$7.3M-$4.8M-$13.4M-$11.1M-$12.2M-$10.8M+11%
Depreciation & amortization$144K$3.0K$3.0K$4.0K$3.0K$3.0K+0%

Balance sheet

USD201920202022202320242025Last year
Cash$5.1M$713K$12.4M$12.4M$9.8M$133M+1258%
Current assets$5.6M$896K$14.7M$13.3M$10.5M$134M+1179%
Total assets$6.6M$3.0M$15.8M$14.1M$10.9M$134M+1135%
Current liabilities$1.2M$8.1M$3.0M$2.6M$3.2M$4.6M+43%
Financial debt—$1.1M————
Total liabilities$1.5M$10.1M$3.3M$2.7M$3.4M$5.0M+47%
Shareholders' equity-$8.3M-$16.6M$12.5M$11.3M$7.5M$129M+1627%
Net debt-$5.1M$428K-$12.4M-$12.4M-$9.8M-$133M-1258%

Ratios

201920202022202320242025Last year
Operating margin-56071.8%-68764.8%—-5228.0%——
Net margin-54252.6%-76346.2%—-4920.0%——
Return on equity——-114.3%-108.7%-192.7%-13.0%
Return on assets-126.8%-341.9%-90.5%-87.5%-132.7%-12.5%
Return on invested capital——-12937.1%———
Interest coverage-967.7x-39.6x-1209.3x-871.3x-1238.3x-1805.6x
Current ratio4.610.114.895.153.2428.95
Quick ratio4.610.114.895.153.2428.95

Data source: SEC EDGAR, company annual reports. Lines a company does not report are left empty. Free cash flow is operating cash flow minus capital expenditure. Ratios use the same formulas as the EdgeScore check.

For information and education only. Not investment advice. Data may contain errors.